Japan's largest clinical laboratory testing operator, running diagnostic tests for hospitals and clinics nationwide.
Japan's largest clinical laboratory testing operator, running diagnostic tests for hospitals and clinics nationwide.
Earns testing fees per sample from hospitals and clinics that send blood and tissue to its laboratories, plus sales of diagnostic reagents through Fujirebio, which it owns, including tests used in Alzheimer's diagnosis. Japan's national fee schedule sets test prices, so volume and efficiency matter more than pricing.
In one line: Japan's Quest Diagnostics / LabCorp.
Moat: narrow (scale, installed base, regulatory licence). Largest lab-testing network in Japan gives scale economics that smaller labs cannot match.
Headquarters: Tokyo, Japan · Founded: 1970 · Employees: 5,157
Size H.U.Group (4544.T) is a Japan Health Care company (Medical/Nursing Services) with a market value of $1.44B, the 587th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,017 on 18 Nov 2026.
Performance Over six months the shares gained 24.4%, against +14.0% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 0.5% over the last twelve months (peer median +7.9%); the operating margin is 2.8% (peer median 6.2%).
Valuation It trades at 39.9× forward earnings against a peer median of 23.7× (4th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.7 points below its cost of capital (5.0% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥249B | ¥247B | ¥243B | ¥237B | ¥261B |
| Revenue growth | — | +2% | +3% | -9% | — |
| Gross profit | ¥72.4B | ¥70.8B | ¥61.3B | ¥57.3B | ¥84.5B |
| EBITDA | ¥27.7B | ¥26.5B | ¥23.1B | ¥16.8B | ¥43.1B |
| Net income | ¥9.96B | ¥6.82B | ¥2.76B | -¥7.55B | ¥15.7B |
| Free cash flow | ¥21.1B | ¥19.2B | ¥20.9B | ¥4.18B | ¥18.3B |
| Capital expenditure | ¥5.10B | ¥4.86B | ¥10.3B | ¥17.6B | ¥21.7B |
| Total debt | ¥60.3B | ¥74.3B | ¥86.7B | ¥81.9B | ¥77.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| H.U.Group 4544.T | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% |
| Quest Diagnostics DGX | $28.6B | +34% | +9% | 15% | 22.4× | 7.2% |
| Labcorp LH | $30.1B | +44% | +6% | 11% | 19.3× | 14.5% |
| BML 4694.T | $932M | +12% | +4% | 7% | 19.8× | -9.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4544.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.9% | -1.6% | 5th highest of 21 |
| 6-month return | +24.4% | +14.0% | 8th highest of 21 |
| Distance from 52-week high | -1.4% | -23.8% | highest of 21 |
| Revenue growth (TTM) | +0.5% | +7.9% | 7th lowest of 21 |
| Operating margin | 2.8% | 6.2% | 8th lowest of 21 |
| Forward P/E | 39.9× | 23.7× | 4th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 9.7% | 6.5% | 6th most demanding of 15 |
| Growth delivered (Del g) | +2.1% | +9.5% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | +7.6 pp | +1.3 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | -1.7 pp | -3.6 pp | 8th highest of 20 |
| EV / EBITDA | 8.9× | 11.7× | 5th cheapest of 14 |
| Net debt / EBITDA | 0.6× | 2.8× | 5th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |